CJC-1295 / Ipamorelin Blend
The CJC-1295 / Ipamorelin combination is one of the most widely used peptide stacks in the research community. By pairing a GHRH analogue (CJC-1295) with a GHRP (Ipamorelin), the blend produces a synergistic and sustained elevation of growth hormone that neither compound achieves alone.
Quick facts
- Half-life
- CJC-1295 DAC: ~6–8 days; Ipamorelin: ~2 hours
- Administration
- Subcutaneous injection
- Primary use
- Growth hormone optimisation, body composition, recovery
How it works
CJC-1295 increases the amplitude of GH pulses by stimulating GHRH receptors, while Ipamorelin increases the frequency of GH pulses via the ghrelin receptor. Together they produce a more complete and physiologically natural GH release pattern, with Ipamorelin's selectivity keeping cortisol and prolactin low.
Reported benefits
- Synergistic GH release — greater than either peptide alone
- Improved lean muscle mass and fat loss over time
- Enhanced recovery, sleep quality, and tissue repair
- Clean side effect profile — Ipamorelin limits cortisol and prolactin elevation
Typical dosing protocol
Dosing
CJC-1295 DAC 1–2 mg/week + Ipamorelin 100–300 mcg 2–3x daily; or pre-mixed blends at equivalent ratios
Cycle length
8–12 weeks, followed by a break of 4+ weeks
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Generally well-tolerated. May cause water retention, tingling, or mild headaches. Not approved for human use in the UK. Not suitable for those with active cancer. Consult a healthcare professional before use.
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.